Results

1–7 of 7 results for Subretinal Delivery

Subretinal Delivery of RGX-314: Gene Therapy for Neovascular Age-Related Macular Degeneration
Ashkan M. Abbey, MD, FASRS, FAAO
Annual Meeting Talks
2023
Subretinal Delivery of Investigational ABBV-RGX-314 for Neovascular Age-Related Macular Degeneration: A Phase II Pharmacodynamic Study
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2024
1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
Subretinal Delivery of RGX-314 for Neovascular AMD: End of Study Phase I/IIa Results
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2021
Precision Subretinal Delivery for Cell and Gene Therapy
Allen C Ho, MD FASRS
Updates from the Field
2019
Precision Subretinal Delivery for Cell and Gene Therapy
Allen C Ho, MD FASRS
Updates from the Field
2019
RGX-314 Gene Therapy Subretinal Delivery for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD)
Jeffrey S. Heier, MD
Annual Meeting Talks
2017